SCM
TEVA icon

Snyder Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Snyder Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-46,359
Closed -$1.86M – 67
2013
Q4 		$1.86M Hold
46,359
– – 0.09% 63
2013
Q3 		$1.75M Sell
46,359
-2,770
-6% -$108K 0.09% 63
2013
Q2 		$1.93M Buy
+49,129
New +$1.91M 0.1% 65

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Snyder Capital Management's TEVA Position: Q1 2014 in Review

Snyder Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2014, closing a stake of 46,359 shares — an estimated $1.86M sold.

Snyder Capital Management first reported a position in TEVA in Q2 2013 and held it in 3 quarters. The position peaked at $1.93M in Q2 2013. 770 funds tracked by Wall St. Rank hold TEVA as of Q1 2014.

  • Snyder Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Snyder Capital Management sold 46,359 Teva Pharmaceuticals shares in Q1 2014, an estimated $1.86M.
  • Snyder Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Snyder Capital Management's Teva Pharmaceuticals position peaked at $1.93M in Q2 2013.
  • 770 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2014.

Based on Snyder Capital Management's 13F filing for Q1 2014, filed 9 May 2014.